UA-45667900-1

Sunday, 5 May 2013

Stress, Neuroinflammation and Magnolia before bed

In earlier posts we learned about two kinds of stress:-
  • Oxidative stress is a biological stress that is measurable (GSH redox) and has been shown to be present in most autistic people.
  • Psychological stress is a feeling we experience in difficult situations and is measurable by sampling the level of the hormone cortisol in saliva.
It would appear that both types of stress are interrelated.
We have already established that oxidative stress in autism can be successfully be treated with NAC.  NAC acts both as an anti-oxidant in its own right and as a precursor chemical to form GSH, the body’s own antioxidant.  NAC is cheap and widely available.
The scientific literature regarding autism includes many references to inflammation of the brain, or neuroinflammation. It turns out that this inflammation is also measurable.  When samples of cerebrospinal fluid (CSF) are taken, elevated levels of chemicals called cytokines are found.  Certain cytokines are markers for neuroinflammation, such as TGF-ß1 and MCP-1.
In studies at Johns Hopkins, a leading teaching hospital in the US, they have tested all their autistic research subjects for neuroinflammation and they all tested positive.  It also appears that this is the result of on-going damage to the brain, not residual damage from the pre-natal or early post natal period.  Such damage was exhibited in autistic subjects of all ages.  These researchers were also able to locate the part of the brain most affected by neuroinflammation.
“Our study showed the cerebellum exhibited the most prominent neuroglial responses. The marked neuroglial activity in the cerebellum is consistent with previous observations that the cerebellum is a major focus of pathological abnormalities in microscopic and neuroimaging studies of patients with autism. Based on our observations, selective processes of neuronal degeneration and neuroglial activation appear to occur predominantly in the Purkinje cell layer (PCL) and granular cell layer (GCL) areas of the cerebellum in autistic subjects. These findings are consistent with an active and on-going postnatal process of neurodegeneration and neuroinflammation.”
There are numerous other researchers who concur with these findings; the problem is that they do not take the logical next step of finding how to reduce this inflammation.  Indeed John’s Hopkins go as far as to tell us
“At present, THERE IS NO indication for using anti-inflammatory medications in patients with autism. Immunomodulatory or anti-inflammatory medications such as steroids (e.g. prednisone or methylprednisolone), immunosupressants (e.g. Azathioprine, methotrexate, cyclophosphamide) or modulators of immune reactions (e.g. intravenous immunoglobulins, IVIG) WOULD NOT HAVE a significant effect on neuroglial activation because these drugs work mostly on adaptive immunity by reducing the production of immunoglobulins, decreasing the production of T cells and limiting the infiltration of inflammatory cells into areas of tissue injury. Our study demonstrated NO EVIDENCE at all for these types of immune reactions. There are on-going experimental studies to examine the effect of drugs that limit the activation of microglia and astrocytes, but their use in humans must await further evidence of their efficacy and safety” 
Here the researchers were experimenting with various chemical including NAC as an antioxidant.
“Activation of microglia has been implicated in the pathogenesis of a variety of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Creutzfeld-Jacob disease, HIV-associated dementia (HAD), stroke, and multiple sclerosis (MS) . It has been found that activated microglia accumulate at sites of injury or plaques in neurodegenerative CNS. Although activated microglia scavenge dead cells from the CNS and secrete different neurotropic factors for neuronal survival, it is believed that severe activation causes inflammatory responses leading to neuronal death and brain injury. During activation, microglia secretes various neurotoxic molecules and express different proteins and surface markers.
Although microglia populate only 2 to 3% of total brain cells in a healthy human being, the number increases up to 12 to 15% during different neurodegenerative diseases. Microglial activation is always associated with neuronal inflammation and ultimately neuronal apoptosis. Although microglial activation may not be always bad as it has an important repairing function as well, once microglia become activated in neurodegenerating microenvironment, it always goes beyond control and eventually detrimental effects override beneficial effects. Therefore, microglial activation is a hallmark of different neurodegenerative diseases and understanding underlying mechanisms for microglial activation is an important area of study. “ 
Another piece of research that looked at activated microglia in a neurological condition (this time Alzheimer’s disease) also used NAC as an antioxidant and anti-inflammatory agent.

Now, to better understand the terminology and the science, a little bit of biology would be useful.  If you wish to skip this part, you can go forward a few pages to the part where I look at practical steps that seem likely to reduce neuroinflammation.
 Here are the key words we need to understand:- 
  • Neurons
  • Neurotransmitters
  • Glial cells
  • Microglia
  • Astrocytes or astroglia
  • Cytokenes

Thanks to Wikipedia I have presented a summary.
 1.  Neurons
A neuron is a cell that processes and transmits information through electrical and chemical signals. A chemical signal occurs via a synapse a specialized connection with other cells. Neurons connect to each other to form neural networks. Neurons are the core components of the CNS (Central Nervous System), which includes the brain and spinal cord. A number of specialized types of neurons exist: sensory neurons respond to touch, sound, light and numerous other stimuli affecting cells of the sensory organs that then send signals to the spinal cord and brain. Motor neurons receive signals from the brain and spinal cord, cause muscle contractions, and affect glansa. Interneurons connect neurons to other neurons within the same region of the brain or spinal cord.

 

2.  Neurotransmitters - interaction between neurons
A neuron affects other neurons by releasing a neurotransmitter that binds to chemical receptors. The effect upon the postsynaptic neuron is determined not by the presynaptic neuron or by the neurotransmitter, but by the type of receptor that is activated. A neurotransmitter can be thought of as a key, and a receptor as a lock: the same type of key can here be used to open many different types of locks. Receptors can be classified broadly as excitatory (causing an increase in firing rate), inhibitory (causing a decrease in firing rate), or modulatory (causing long-lasting effects not directly related to firing rate).
The two most common neurotransmitters in the brain, and GABA, have actions that are largely consistent. Glutamate acts on several different types of receptors, and have effects that are excitatory at ionotropic receptors and a modulatory effect at metabotropic receptors. Similarly GABA acts on several different types of receptors, but all of them have effects (in adult animals, at least) that are inhibitory. Because of this consistency, it is common for neuroscientists to simplify the terminology by referring to cells that release glutamate as "excitatory neurons," and cells that release GABA as "inhibitory neurons." Since over 90% of the neurons in the brain release either glutamate or GABA, these labels encompass the great majority of neurons.

GABA is very important in autism and we will return to it in greater depth when we will look at the three types of GABA receptors.

3.   Glial cells
Glial cells are non-neuronal cells that maintain homeostasis and provide support and protection for neurons in the brain, and for neurons in other parts of the nervous system such as in the autonomic nervous system.
Four main functions of glial cells have been identified:
  1. To surround neurons and hold them in place,
  2. To supply nutrients and oxygen to neurons,
  3. To insulate one neuron from another,
  4. To destroy pathogens and remove dead neurons.
Glial cells do modulate neurotransmission, although the mechanisms are not yet well understood.
 
Functions

Some glial cells function primarily as the physical support for neurons. Others regulate the internal environment of the brain, especially the fluid surrounding neurons and their synapses, and nutrify neurons. During early embryogenesis glial cells direct the migration of neurons and produce molecules that modify the growth of axons and dendrites. Recent research indicates that glial cells of the hippocampus and cerebellum participate in synaptic transmission, regulate the clearance of neurotransmitters from the synaptic cleft, and release gliotransmitters such as ATP, which modulate synaptic function.
Glial cells were not believed to have chemical synapses or to release transmitters. They were considered to be the passive bystanders of neural transmission. However, recent studies have shown this to be untrue. For example, astrocytes are crucial in clearance of neurotransmitters from within the synaptic cleft, which provides distinction between arrivals of action potentials and prevents toxic build-up of certain neurotransmitters such as glutamate (excitotoxicity). It is also thought that glia play a role in many neurological diseases, including Alzheimer’s disease. Furthermore, at least in vitro, astrocytes can release gliotransmitter glutamate in response to certain stimulation.
Glia have a role in the regulation of repair of neurons after injury. In the CNA (Central Nervous System), glia suppress repair. Glial cells known as astrocytes enlarge and proliferate to form a scar and produce inhibitory molecules that inhibit regrowth of a damaged or severed axon. In the PNS (Peripheral Nervous System), glial cells known as Schwann cells promote repair. After axonal injury, Schwann cells regress to an earlier developmental state to encourage regrowth of the axon. This difference between PNS and PNS raises hopes for the regeneration of nervous tissue in the CNS. For example a spinal cord may be able to be repaired following injury or severance.

4.  Microglia
Microglia are a type of glial cell that are the resident macrophages of the brain and spinal cord, and thus act as the first and main form of active immune defense in the CNS. Macrophages are highly specialized in removal of dying or dead cells and cellular debris. This role is important in chronic inflammation, as the early stages of inflammation are dominated by neutrophil granulocytes, which are ingested by macrophages if they come of age.
Microglia constitute 20% of the total glial cell population within the brain.] Microglia (and astrocytes) are distributed in large non-overlapping regions throughout the brain and spinal cord.  Microglia are constantly scavenging the CNS for plaques, damaged neurons and infectious agents. The brain and spinal cord are considered "immune privileged" organs in that they are separated from the rest of the body by a series of endothelial cells known as the blood brain barrier (BBB), which prevents most infections from reaching the vulnerable nervous tissue. In the case where infectious agents are directly introduced to the brain or cross the blood–brain barrier, microglial cells must react quickly to decrease inflammation and destroy the infectious agents before they damage the sensitive neural tissue. Due to the unavailability of antibodies from the rest of the body (few antibodies are small enough to cross the blood brain barrier), microglia must be able to recognize foreign bodies, swallow them, and act as antigen presenting cells activating T-cells. Since this process must be done quickly to prevent potentially fatal damage, microglia are extremely sensitive to even small pathological changes in the CNS. They achieve this sensitivity in part by having unique potassium channels that respond to even small changes in extracellular potassium.
5.  Astrocytes or astroglia,
Astrocytes or astroglia are characteristic star-shaped glial cells in the brain and spinal cord. They are the most abundant cell of the human brain. They perform many functions, including biochemical support of endothelial cells that form the blood-brain barrier, provision of nutrients to the nervous tissue, maintenance of extracellular ion balance, and a role in the repair and scarring process of the brain and spinal cord following traumatic injuries.
Research since the mid-1990s has shown that astrocytes propagate intercellular Ca2+- waves over long distances in response to stimulation, and, similar to neurons, release transmitters (called gliotransmitters) in a Ca2+-dependent manner. Data suggest that astrocytes also signal to neurons through Ca2+-dependent release of glutamate. Such discoveries have made astrocytes an important area of research within the field of neuroscience..
Previously in medical science, the neuronal network was considered the only important one, and astrocytes were looked upon as gap fillers. More recently, the function of astrocytes has been reconsidered, and are now thought to play a number of active roles in the brain, including the secretion or absorption of neural transmitters and maintenance of the blood–brain barrier.  Following on this idea the concept of a "tripartite synapse" has been proposed, referring to the tight relationship occurring at synapses among a presynaptic element, a postsynaptic element and a glial element.
  • Structural: They are involved in the physical structuring of the brain. Astrocytes get their name because they are "star-shaped". They are the most abundant glial cells in the brain that are closely associated with neuronal synapses. They regulate the transmission of electrical impulses within the brain.
  • Glycogen fuel reserve buffer: Astrocytes contain glycogen and are capable of glycogenesis. The astrocytes next to neurons in the frontal cortex and hippocampus store and release glycogen. Thus, Astrocytes can fuel neurons with glucose during periods of high rate of glucose consumption and glucose shortage. Recent research suggests there may be a connection between this activity and exercise.
  • Metabolic support: They provide neurons with nutrients such as lactate.
  •  Blood-brain barrier: The astrocyte end-feet encircling endothelial cells were thought to aid in the maintenance of the blood–brain barrier, but recent research indicates that they do not play a substantial role; instead, it is the tight junctions and basal lamina of the cerebral endothelial cells that play the most substantial role in maintaining the barrier. However, it has recently been shown that astrocyte activity is linked to blood flow in the brain, and that this is what is actually being measured in fMRI.
  • Transmitter uptake and release: Astrocytes express plasma membrane transporters such as glutamate transporters for several neurotransmitters, including glutamate, ATP, and GABA. More recently, astrocytes were shown to release glutamate or ATP in a vesicular, Ca2+-dependent manner.
  •  Regulation of ion concentration in the extracellular space Astrocytes express potassium channels at a high density. When neurons are active, they release potassium, increasing the local extracellular concentration. Because astrocytes are highly permeable to potassium, they rapidly clear the excess accumulation in the extracellular space. If this function is interfered with, the extracellular concentration of potassium will rise, leading to neuronal depolarization by the Goldman equation. Abnormal accumulation of extracellular potassium is well known to result in epileptic neuronal activity.
  • Vasomodulation: Astrocytes may serve as intermediaries in neuronal regulation of blood flow.
  • Nervous system repair: Upon injury to nerve cells within the central nervous system, astrocytes fill up the space to form a glial scar, repairing the area and replacing the CNS cells that cannot regenerate.
  • Long-term potentiation: Scientists continue to argue back and forth as to whether or not astrocytes integrate learning and memory in the hippocampus. It is known that glial cells are included in neuronal synapses, but many of the LTP studies are performed on slices, so scientists disagree on whether or not astrocytes have a direct role of modulating synaptic plasticity.
 
6.  Cytokines
Cytokines are small signaling molecules used for cell signaling.  The term cytokine encompasses a large and diverse family of regulators produced throughout the body by cells of diverse embryological origin.
The term cytokine has been used to refer to the immunomodulating agents, such as interleukins and interferons. Biochemists disagree as to which molecules should be termed cytokines and which hormones. As we learn more about each, anatomic and structural distinctions between the two are fading. Classic protein hormones circulate in nanomolar (10-9M) concentrations that usually vary by less than one order of magnitude. In contrast, some cytokines (such as IL-6) circulate in picomolar (10-12M) concentrations that can increase up to 1,000-fold during trauma or infection. The widespread distribution of cellular sources for cytokines may be a feature that differentiates them from hormones. Virtually all nucleated cells, but especially endo/epithelial cells and resident macrophages (many near the interface with the external environment) are potent producers of IL-1, IL-6, and TNF-a. In contrast, classic hormones, such as insulin, are secreted from discrete glands (e.g., the pancreas).  As of 2008, the current terminology refers to cytokines as immunomodulating agents. However, more research is needed in this area of defining cytokines and hormones.
Part of the difficulty with distinguishing cytokines from hormones is that some of the immunomodulating effects of cytokines are systemic rather than local. Further, as molecules, cytokines are not limited to their immunomodulatory role. For instance, cytokines are also involved in several developmental processes during embyrogenesis.

Several inflammatory cytokines are induced by oxidant stress. The fact that cytokines themselves trigger the release of other cytokines and also lead to increased oxidant stress makes them important in chronic inflammation, as well as other immunoresponses, such as fever and acute phase proteins of the liver (IL-1,6,12, INF-a).
  
Practical Steps to reduce neuroinflammation
Neuroscience is both complex and an evolving science; much remains unknown and so often there cannot be definite answers; rather judgements based on the balance of probabilities.
What is clear is that in autism we have oxidative stress and inflammation.  There also appears to be a vicious circle where the inflammation messenger itself makes that inflammation worse.  In some cases, it is the oxidative stress that triggers the inflammation; in other cases the inflammation may have other causes.
A more complex explanation relates to where the signal to the microglia came from in the first place.  Mast cells from the immune system are proposed to be the source of this signal.
For the time being let us focus on the simpler solution; that the anti-oxidant should also be the anti-inflammatory agent.  Surprise, surprise, our friend NAC is being used in numerous studies as the anti-inflammatory agent.
This is good news for Monty; it may be that NAC is not just reducing his state of oxidative stress, but gradually his neuroinflammation as well.  It certainly does seem to be doing him good.  As indicated in the research, the effect of NAC seems to be highly dose dependent.
But not to have all our eggs in one basket, it would be nice to have another anti-neuroinflammatory agent.  It seems there is one at hand, but we have to look to the East to find it.
 
Obovatol
The bark of the magnolia tree has been used in Korean, Chinese and Japanese medicine for more than a thousand years.  It seems that one compound in particular within magnolia, obovatol, has powerful properties to reduce neuroinflammation.
In another paper
and another
This is all experimental but it is clear that in theory at least, obovatol looks very interesting.
For a wider view of the medical properties of the magnolia family, there is an excellent paper from Korea that reviews the possible mechanisms. Therapeutic applications of compounds in the Magnolia family
 The proposed benefits are in the treatment of:- 
  • cancer
  • neuronal disease
  • inflammatory disease
  • cardiovascular disease 
The four active compounds are: 
  1. magnolol
  2. honokiol
  3. 4-O-methylhonokiol
  4. obovatol 
Also, anxiolytic-like effects of obovatol appeared to be mediated by the GABA benzodiazepine receptor Cl− channel opening and obovatol potentiated pentobarbital-induced sleeping time through GABA receptors/Cl− channel activation.

This data suggest that components of Magnolia could be used for treating anxiety, and its effect may be linked to GABA receptor/Cl− channel activation. 
Anti-inflammatory mechanisms of Magnolia have been reported to be associated with the suppression of NO production, the expression of iNOS, IL-1β, TNF-α and COX, the generation of prostaglandins, thromboxanes and leukotrienes, and the activation of MAPKs, AP-1 and NF-κB.
 
Magnolia Bark Extract
Magnolia bark extract is extensively produced in China and sold inexpensively by the supplement industry.  The individual compounds could be separated, as in the Korean research, but the extract that is sold is just a mixture of what happened to be in that batch of bark.  If you read the reviews, it seems that many people experience a reduction in cortisol allowing them to sleep better; reduced anxiety is widely reported.  It even seems to stop some people snoring, which I am certainly all in favour of.
So while it is far from the scientific basis on which you could use NAC, it would seem that Magnolia bark extract will unlikely do harm and just might do some good as an anti-neuroinflammatory agent.  In about 20 years, the research will show whether you were wasting your money, or whether you were a pioneering early-adopter.
I think I will do some primary research on this one and be a pioneer.

 

Monday, 29 April 2013

Vitamin P may be good for you!

Now if the tittle makes sense to you, either you are a Prozac fan, or you were around in the 1940s and 50s when there actually was a vitamin P.

This blog is about autism, and in the US lots of such kids are prescribed the powerful antidepressant Prozac. We are more interested in the other vitamin P; these days they are called flavonoids.  This post will meander into other health problems but will return to ASD later on.

Flavonoids are found in plants and there are 5,000 of them.  In plants they have various functions, one of which is to provide colour (usually yellow, red and blue); in humans it is proposed that certain flavonoids may account for the beneficial properties of certain foods, ranging from chocolate to red wine.

There are many food supplements sold that contain flavonoids, three of the popular ones seem to be:-
 
·         Rutin
·         Quercetin
·         Luteolin

There is even a special mix made for autistic people called NeuroProtek.
 

In Vitro or in Vivo?

Some things work well in the test tube but not so well in us humans.  In vitro means in the glass and in vivo means in us living creatures.

Well, flavonoids have wonderful antioxidant properties, but it seems that is in only true in the test tube.  In vivo they are rather a flop.  Yet, if you read all the advertising for these flavonoid supplements, they rave about the antioxidant properties.

 
A great discussion of flavonoids is presented by the Linus Pauling Institute at Oregon State University. I have summarized much of it here and added the autism part.

 
Some flavonoids are good for you, but not as antioxidants

If flavonoids are not good antioxidants, why are they supposed to be good for you?  It seems that they have an entirely different role as signalling molecules.

Concentrations of flavonoids required to affect cell-signaling pathways are considerably lower than those required to affect cellular antioxidant capacity. Flavonoid metabolites may retain their ability to interact with cell-signaling proteins even if their antioxidant activity is diminished. Effective signal transduction requires proteins known as kinases that catalyse the phosphorylation (transferring a phosphate group (-PO4)) of target proteins at specific sites.

The results of numerous studies in cell culture suggest that flavonoids may affect chronic disease by selectively inhibiting kinases.

Cell growth and proliferation are also regulated by growth factors that initiate cell-signaling cascades by binding to specific receptors in cell membranes. Flavonoids may alter growth factor signaling by inhibiting receptor phosphorylation or blocking receptor binding by growth factors.

All this leads naturally to think that modulation of cell-signaling pathways by flavonoids could help prevent cancer.  Mechanisms proposed include:-

Stimulating phase II detoxification enzyme activity: Phase II detoxification enzymes catalyse that promote the excretion of potentially toxic or carcinogenic chemicals.

Preserving normal cell cycle regulation: Once a cell divides, it passes through a sequence of stages collectively known as the cell cycle before it divides again. Following DNA damage, the cell cycle can be transiently arrested at damage checkpoints, which allows for DNA repair or activation of pathways leading to cell death if the damage is irreparable. Defective cell cycle regulation may result in the propagation of mutations that contribute to the development of cancer.

Inhibiting proliferation and inducing apoptosis (cell death): Unlike normal cells, cancer cells proliferate rapidly and lose the ability to respond to cell death signals that initiate apoptosis.

Inhibiting tumor invasion and angiogenesis: Cancerous cells invade normal tissue aided by enzymes called matrix-metalloproteinases. To fuel their rapid growth, invasive tumors must develop new blood vessels by a process known as angiogenesis.

Decreasing inflammation: Inflammation can result in locally increased production of free radicals by inflammatory enzymes, as well as the release of inflammatory mediators that promote cell proliferation and angiogenesis (creation of new blood vessels) and inhibit apoptosis (beneficial cell death).

Modulation of cell-signaling pathways by flavonoids could help prevent cardiovascular disease by:

Decreasing inflammation: Atherosclerosis is now recognized as an inflammatory disease, and several measures of inflammation are associated with increased risk of heart attack.

Decreasing vascular cell adhesion molecule expression: One of the earliest events in the development of atherosclerosis is the recruitment of inflammatory white blood cells from the blood to the arterial wall.

Increasing endothelial nitric oxide synthase (eNOS) activity: eNOS is the enzyme that catalyzes the formation of nitric oxide by vascular endothelial cells. Nitric oxide is needed to maintain arterial relaxation. Impaired nitric oxide-dependent vasodilation is associated with increased risk of  cardiovascular disease.

Decreasing platelet aggregation: Platelet aggregation is one of the first steps in the formation of a blood clot that can occlude a coronary or cerebral artery, resulting in myocardial infarction or stroke, respectively. Inhibiting platelet aggregation is considered an important strategy in the primary and secondary prevention of cardiovascular disease.

 
Green tea and even red wine were supposed to have wonderful antioxidant properties; apparently this is not true after all.  They do seem to be good for you, but for completely different reasons.

People who consume larger amounts of flavonoids do seem to be healthier; but sadly that does not prove that eating flavonoids makes you healthy.  It might just be that a healthy diet just happens to be flavonoid-rich.

There is on-going research and multiple clinical trials into the possible benefits of flavonoids in these areas:-

Cardiovascular Disease

The results of some controlled clinical trials suggest that relatively high intakes of some flavonoid-rich foods and beverages, including black tea, purple grape juice, and cocoa (dark chocolate) has health benefits.

Cancer

The research is ongoing, it seems to show that those people with a diet rich in flavonoids have a lower risk of certain cancers; but it seems that tea consumption has no benefit here.

Neurodegenerative Disease

It is not clear to what extent flavonoids can cross into the brain thought the BBB (blood brain barrier).  Research is ongoing to see whether Parkinson’s disease, Alzheimer’s and dementia are correlated to flavonoids in the diet.  With 5,000 flavonoids this will take some time!

 
Flavonoid Content in Food
 
There are 5 principal types of flavonoids

1.    ANTHOCYANIDINS

Examples:- Cyanidin, Delphinidin, Malvidin, Pelargonidin, Peonidin, Petunidin

Supplements available include: Bilberry, elderberry, black currant, blueberry, red grape, and mixed berry extracts.  Don’t forget the red wine.

 
2.    FLAVONOLS

Examples:- Quercetin, Kaempferol, Myricetin, Isorhamnetin

The flavonol aglycone, quercetin, and its glycoside rutin are available as dietary supplements without a prescription in the U.S. Other names for rutin include rutinoside, quercetin-3-rutinoside, and sophorin. Citrus bioflavonoid supplements may also contain quercetin or rutin.

Flavonols are found in yellow onions, scallions, kale, broccoli, apples, berries and teas.

3.    FLAVONES

Examples:-  Luteolin, Apigenin

The peels of citrus fruits are rich in polymethoxylated flavones: tangeretin, nobiletin, and sinensetin. Although dietary intakes of these naturally occurring flavones are generally low, they are often present in citrus bioflavonoid supplements.

Flavones are found in parsley, thyme, celery, hot peppers, and chamomile

4.     LAVANONES

Examples:- Hesperetin, Naringenin, Eriodictyol

Citrus bioflavonoid supplements may contain glycosides of hesperetin (hesperidin), naringenin (naringin), and eriodictyol (eriocitrin). Hesperidin is also available in hesperidin-complex supplements

Lavanones are found in citrus fruits and juices, e.g., oranges, grapefruits, lemons


5.    FLAVANOLS 

A.    Monomers (Catechins)


B.    Dimers and Polymers:
examples:-  Theaflavins,  Thearubigins, Proanthocyanidins

Here is where to find them:-

Catechins: Teas (particularly green and white), chocolate, grapes, berries, apples
Theaflavins, Thearubigins: Teas (particularly black and oolong)
Proanthocyanidins: Chocolate, apples, berries, red grapes, red wine

 

USDA Database for the Flavonoid Content of Selected Foods

If you want to know which food contains how much of each flavonoid, just click on the link to go to a large database held by the US Department of Agriculture.
 

 
Another flurry of Patents

Not for the first time, I have noted that a flurry of patents have been filed in connection with autism.  This time it’s a couple of guys from the University of South Florida who see promise in the flavonoids :-  luteolin, diosmin, and diosmin's aglycone form, diosmetin.
 
The more prolific publisher is Theoharis Theoharides.  Here is an excerpt, from his patent:-
  
 






Theoharides is a big believer the benefit of luteolin.  Here is his main hypothesis Neuro-inflammation, blood-brain barrier, seizures and autism.


I like the fact that he is questioning the permeability of the BBB (blood brain barrier) in autism.  It seems entirely plausible and would account for many things.

  

Conclusion
 
Well I was already convinced that red wine was good for me.  Now I just have add the right vitamin P.

Time for a cup of tea, better make it chamomile (for the luteolin) and some dark chocolate.

Monty is still rather young for the red wine.  If he was French, though ….


 

Thursday, 25 April 2013

Oxytocin - Not to be sniffed at?


Things seem to move slowly in the world of autism research.

Since the 1970s it has been discussed that oxytocin might be a wonder hormone that could make you feel better.  The problem was that it cannot cross the BBB (blood brain barrier).  Oxytocin secreted from the pituitary gland cannot re-enter the brain because of the BBB. Instead, the behavioral effects of oxytocin are thought to reflect release from centrally projecting oxytocin neurons, different from those that project to the pituitary gland.

Oxytocin is destroyed in the gastrointestinal tract, so must be administered by injection or as a nasal spray.  Because of the BBB any injected oxytocin should fail to enter the brain.  The nasal method of delivery uses the nasal membrane as a means of transferring the oxytocin.  But when it passes through that membrane it surely enters the blood and then will struggle to cross the BBB.  Note that most of oxytocin’s primary functions are outside of the brain; the ones relevant to autism however occur inside the brain.

For several years it was assumed that the nasal spray oxytocin could not possible affect behaviours, since it could not enter the brain.  This view now seems to be in question.  It seems fair to assume that either a small portion of the oxytocin manages to cross the BBB, or perhaps the BBB is indeed more permeable in some people.  There is a school of thought that believes that autism is caused by a BBB malfunction, and certain harmful substances that should have been kept out of the brain, were let in.  If this were indeed the case, perhaps that faulty BBB would also let the oxytocin in?

I had rather assumed that after 30-40 years, if there was some element of truth in the therapeutic value of oxytocin, it would have been proved by now.


The Good(ish) News

A five year study of the benefits of oxytocin nasal spray in autism will start this year in the US at some leading hospitals including Massachusetts General Hospital.  The study is managed by researcher Dr Linmarie Sikich, MD of the ASPIRE Research Program at the University of North Carolina-Chapel Hill.  The study will have 300 participants.

It is a follow-on study to one already completed by Dr Sikich and funded in part by Autism Speaks.  This initial study involved just 25 children, but seemed to have a positive outcome.



The Science Part

As I mentioned, there has been a great deal of research into Oxytocin.  Here is free paper called Social effects of oxytocinin humans: context and person matter.

A study was carried out in 2012 on adults with autism; the researchers did not seem to be that excited about the results, but suggested that the results warranted further studies.  The study is free to access:  Intranasal oxytocin versus placebo in the treatment of adults with autismspectrum disorders: a randomized controlled trial

A more typical study is this one:- Oxytocin, vasopressin and pair bonding: Implications for autism.  It sounds interesting, but in fact is more about the mating patterns of prairie voles vs. meadow voles.

In 2003 a study using an infusion of oxytocin vs. a placebo looked at the effects on repetitive behaviours:-  Oxytocin Infusion Reduces RepetitiveBehaviors in Adults with Autistic and Asperger’s Disorders
 
I wish these scientists would decide once and for all if oxytocin can cross the BBB.  If it cannot, then a huge amount of time and money is being wasted.

 

Conclusion

It seems that oxytocin spray does not appear to do harm.  It is already available over the counter (OTC) and indeed over the internet.  If you take too much oxytocin, some pretty strange things will start happening, since it is a hormone with many specific roles in the human body, other than making you feel good.

Some researchers and parents seem very impressed by its effects on autistic subjects.  Other scientists think it cannot possibly cross into the brain.

In five years’ time we should know conclusively whether it really does “work”.
 
I would put it in my plausible, but not proven, category. 

If you do try it at home, do let us all know the results.


 

Wednesday, 24 April 2013

Spinocerebellar Ataxia (SCA) and Autism

Reviewing the literature on autism, various terms are used to classify the various shades of autism.-

·         Autism

·         High Functioning autism

·         Asperger’s syndrome

·         Autistic Spectrum Disorder (ASD)

 
The trend coming from the US is to classify all the disorders as a single disorder, and then by widening the definition, draw in an even greater pool of subjects; hence the so-called autism epidemic.

This is extremely un-scientific and indeed unhelpful.  Autism is just a collection of observable and indeed measurable behaviors.  The extent to which a subject is affected by each type of behavior varies wildly.

When a patient goes to his doctor, an initial investigation might involve taking temperature, measuring pulse, examining ear, nose and throat.  The doctor does not simply conclude the patient is sick; he has to look for a specific combination of symptoms and measurable variables and make a specific diagnosis.

Now consider a rare brain disorder, Spinocerebellar Ataxia (SCA).

SCA affects about 0.025% of the population.  Moderate to severe autism affects about 0.3% of the population.  We can say that autism is 12 times more prevalent than SCA, or if we use the latest American definition and use CDC data we would say that autism is 40 times more prevalent than SCA.

Yet SCA seems far better understood and thoroughly researched than ASD.  You need go no further than Wikipedia, to see that 60 sub-types have been identified.  The disease itself is a progressive and degenerative but each sub-type has a unique cause and indeed a unique prognosis.  Usually the diagnosis comes after examination by a neurologist, which includes a physical exam, family history, and testing such as an MRI of the brain and spine and a spinal tap.

The prognosis is not good for any of the 60 types, but at least in Japan the pharmaceutical industry did develop a drug therapy.  Somewhat bizarrely, this therapy is unavailable outside Japan.  Equally bizarre is that a drug like Prozac, which is commonly prescribed to children in the US with ASD, is illegal in Japan.

The major sub-types of SCA are shown in the table.  




Implications of multiple types of autism

If autism also has many variants, it likely will also have many different causes and therefore likely have different pharmacological interventions.

This has a massive impact on clinical trials for possible therapies.

The fact that a subgroup of 20% might respond to a treatment but 80% do not, should perhaps be viewed as a success and not a failure.

Drug therapies must be related to a specific biological failure.

If, as seems likely, the same aberrant behaviour can be caused by more than one biological failure, then researchers have to be very much more wary how they conduct their clinical trials and more importantly how they interpret the results.